Ann: HepaFat-AI gains US FDA clearance, page-57

one of the best announcement on ASX today RHT

Some facts About RHT: FDA approval this will bring below mentioned value to the company

1.8 to 2.3 billion people living with non alcoholic fatty liver disease (NAFLD)Each NAFLD test cost roughly around $100, but I take $50 to call it fair value

1% of that population =18million x 50 dollars per scan = $900 million revenue
10% of the population = 180mx $50 per scan = $9billion revenue

This valuation based on only 1 product, What should be real value if we consider all 6 products RHT has

As per their last announcement RHT working on other AI projects for approval . The company filed a provisional patent with IP Australia covering the application of novel Antisense Oligonucleotides (ASOs) to treat liver related disease. If successfully granted, the patent would have a term of 20 years from the complete (PCT) filing date (see ASX announcements dated 25 May 2020 and 26 May 2020).• A 510(k) application for regula clearance was submitted to the United States Food and Drug Administration (“US FDA”) for the Company’s newly developed AI solution, HepaFat-AI (see ASX announcement dated 6 April 2020).• The Company’s cash on hand as of 30 June 2020 was $6.97m, an increase of $115K over the March 2020 quarter.